Literature DB >> 21364685

WIN Consortium--challenges and advances.

John Mendelsohn1, Thomas Tursz, Richard L Schilsky, Vladimir Lazar.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21364685     DOI： 10.1038/nrclinonc.2010.230

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

Review 1.  Methodological and practical challenges for personalized cancer therapies.

Authors:  Ignacio I Wistuba; Juri G Gelovani; Jörg J Jacoby; Suzanne E Davis; Roy S Herbst
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675
  1 in total
  7 in total

Review 1.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

2.  Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Authors:  Julie A Theurer; William Stecho; John Yoo; Keith Kwan; Bret Wehrli; Vimla Harry; Morgan Black; Nicole Pinto; Eric Winquist; David Palma; Suzanne Richter; John W Barrett; S Danielle MacNeil; Kevin Fung; Christopher J Howlett; Anthony C Nichols
Journal:  Pathol Oncol Res       Date:  2015-08-14       Impact factor: 3.201

3.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Authors:  J Rodon; J C Soria; R Berger; G Batist; A Tsimberidou; C Bresson; J J Lee; E Rubin; A Onn; R L Schilsky; W H Miller; A M Eggermont; J Mendelsohn; V Lazar; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-23       Impact factor: 32.976

Review 4.  Mouse hospital and co-clinical trial project--from bench to bedside.

Authors:  John G Clohessy; Pier Paolo Pandolfi
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 5.  Predictive, personalized, preventive, participatory (P4) cancer medicine.

Authors:  Leroy Hood; Stephen H Friend
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

6.  Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.

Authors:  Leticia De Mattos-Arruda; Jordi Rodon
Journal:  Oncologist       Date:  2013-10-17

Review 7.  Somatic variation and cancer: therapies lost in the mix.

Authors:  Andrew V Biankin; Thomas J Hudson
Journal:  Hum Genet       Date:  2011-06-05       Impact factor: 5.881
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.